Evidence map›Paper›PMID 27078840›Full record

ArticlePloS one2016

Genetic Variants Associated with Colorectal Adenoma Susceptibility.

Anna Abulí, Antoni Castells, Luis Bujanda, Juan José Lozano, Xavier Bessa, Cristina Hernández, Cristina Álvarez-Urturi, Maria Pellisé, Clara Esteban-Jurado, Elizabeth Hijona and 7 more

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Interaction of CCND2, CDKN1A, and POLD3 Variants in Mexican Patients with Colorectal Cancer.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022
    Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Anna AbulíDepartment of Gastroenterology, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Pompeu Fabra University, Passeig Marítim 25-29, 08003, Barcelona, Catalonia, Spain.
Antoni CastellsDepartment of Gastroenterology, Hospital Clínic, CIBERehd, IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Catalonia, Spain.
Luis BujandaDepartment of Gastroenterology, Hospital Donostia/Instituto Biodonostia, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco (UPV/EHU), Doctor Begiristain Kalea, 20014, Donostia/Gipuzkoa, Spain.
Juan José LozanoPlataforma de Bioinformática, CIBERehd, Villarroel 170, 08036, Barcelona, Catalonia, Spain.
Xavier BessaDepartment of Gastroenterology, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Pompeu Fabra University, Passeig Marítim 25-29, 08003, Barcelona, Catalonia, Spain.
Cristina HernándezDepartment of Epidemiology and Evaluation, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim 25-29, 08003, Barcelona, Catalonia, Spain.
Cristina Álvarez-UrturiDepartment of Gastroenterology, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Pompeu Fabra University, Passeig Marítim 25-29, 08003, Barcelona, Catalonia, Spain.
Maria PelliséDepartment of Gastroenterology, Hospital Clínic, CIBERehd, IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Catalonia, Spain.
Clara Esteban-JuradoDepartment of Gastroenterology, Hospital Clínic, CIBERehd, IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Catalonia, Spain.
Elizabeth HijonaDepartment of Gastroenterology, Hospital Donostia/Instituto Biodonostia, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco (UPV/EHU), Doctor Begiristain Kalea, 20014, Donostia/Gipuzkoa, Spain.
Andrea BurónDepartment of Epidemiology and Evaluation, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim 25-29, 08003, Barcelona, Catalonia, Spain.
Francesc MaciàDepartment of Epidemiology and Evaluation, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim 25-29, 08003, Barcelona, Catalonia, Spain.
Jaume GrauUnitat d'Avaluació, Suport i Preventiva, Hospital Clínic, Roselló 138, 08036, Barcelona, Catalonia, Spain.
Rafael GuaytaPlanning and Research Unit, Consell de Collegis Farmacèutics de Catalunya, Girona 64, 08009, Barcelona, Catalonia, Spain.
Sergi Castellví-BelDepartment of Gastroenterology, Hospital Clínic, CIBERehd, IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Catalonia, Spain.
Montserrat AndreuDepartment of Gastroenterology, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Pompeu Fabra University, Passeig Marítim 25-29, 08003, Barcelona, Catalonia, Spain.
PROCOLON research group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCommon low-penetrance genetic variants have been consistently associated with colorectal cancer risk.

aimTo determine if these genetic variants are associated also with adenoma susceptibility and may improve selection of patients with increased risk for advanced adenomas and/or multiplicity (≥ 3 adenomas).

methodsWe selected 1,326 patients with increased risk for advanced adenomas and/or multiplicity and 1,252 controls with normal colonoscopy from population-based colorectal cancer screening programs. We conducted a case-control association study analyzing 30 colorectal cancer susceptibility variants in order to investigate the contribution of these variants to the development of subsequent advanced neoplasia and/or multiplicity.

resultsWe found that 14 of the analyzed genetic variants showed a statistically significant association with advanced adenomas and/or multiplicity: the probability of developing these lesions increased with the number of risk alleles reaching a 2.3-fold risk increment in individuals with ≥ 17 risk alleles.

conclusionsNearly half of the genetic variants associated with colorectal cancer risk are also related to advanced adenoma and/or multiplicity predisposition. Assessing the number of risk alleles in individuals within colorectal cancer screening programs may help to identify better a subgroup with increased risk for advanced neoplasia and/or multiplicity in the general population.

Indexed as

Polymorphism, Single NucleotideAdenomaAgedAllelesCase-Control StudiesColorectal NeoplasmsFemaleGene FrequencyGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansLogistic ModelsMaleMiddle AgedMultivariate Analysis

Identifiers

PMID27078840
PMCPMC4831735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.